We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
Read MoreHide Full Article
On Aug 23, we issued an updated research report on Medtronic plc (MDT - Free Report) . While we are encouraged by the company’s globally accepted advanced therapies, its escalating costs and expenses however, raise concerns. The stock has a Zacks Rank #3 (Hold).
Over the past three months, shares of Medtronic have outperformed the industry. The stock has grown 9.9% compared with the industry’s 5.2% rise.
Notably, Medtronic posted better-than-expected numbers in first-quarter fiscal 2019. All major business groups contributed to its solid top-line growth at CER, which highlighted sustainability across groups and regions in addition to displaying a feat of synergy targets. We are also impressed by the company’s solid growth trend in the United States making several strategic divestitures as well as the healthy global acceptance of its advanced therapies.
Also, the gradually stabilizing Cardiac Rhythm & Heart Failure market holds promise. Moreover, it is heartening to note that in the reported quarter, Medtronic reported 2.6% rise within this segment, primarily banking on low-single-digit growth in Arrhythmia Management at CER. Besides contributions from the rollout of Micra Transcatheter Pacing System and Azure pacemaker, the strong quarterly increase was also on the back of growth in atrial fibrillation Solutions at CER, Infection Control and Mechanical Circulatory Support business.
Additionally, strong demand for the company's suite of quadripolar cardiac resynchronization therapy-pacemakers along with growth in Mechanical Circulatory Support drove Heart Failure division revenues.
The FDA approval for Deep Brain Stimulation therapy as an adjunctive treatment to reduce partial-onset seizures raises hope for the company in the target medical market. Medtronic is also focusing on the geographical diversification of its businesses. The company is highly positive about its foray into the $1-billion standalone CGM (continuous glucose monitoring) market with its Guardian Connect.
We are currently upbeat about the company’s recently-launched restructuring initiative called Enterprise Excellence plan, aimed at $3-billion annual growth run rate savings by the end of fiscal 2022. Per Medtronic, this new program has been designed to increase its effectiveness as well as heighten growth-related reinvestment ability alongside providing a consistent boost to its margin expansion and driving the EPS leverage.
On the flip side, the company has been grappling with steep costs and expenses, weighing heavily on its margins. Also, its 2019 guidance remains conservative on the apprehension of a significant currency headwind.
Inogen has an expected long-term earnings growth rate of 22.5% while the same for Integer Holdings and Patterson Companies is pegged at 15% and 8.3%, respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
On Aug 23, we issued an updated research report on Medtronic plc (MDT - Free Report) . While we are encouraged by the company’s globally accepted advanced therapies, its escalating costs and expenses however, raise concerns. The stock has a Zacks Rank #3 (Hold).
Over the past three months, shares of Medtronic have outperformed the industry. The stock has grown 9.9% compared with the industry’s 5.2% rise.
Notably, Medtronic posted better-than-expected numbers in first-quarter fiscal 2019. All major business groups contributed to its solid top-line growth at CER, which highlighted sustainability across groups and regions in addition to displaying a feat of synergy targets. We are also impressed by the company’s solid growth trend in the United States making several strategic divestitures as well as the healthy global acceptance of its advanced therapies.
Also, the gradually stabilizing Cardiac Rhythm & Heart Failure market holds promise. Moreover, it is heartening to note that in the reported quarter, Medtronic reported 2.6% rise within this segment, primarily banking on low-single-digit growth in Arrhythmia Management at CER. Besides contributions from the rollout of Micra Transcatheter Pacing System and Azure pacemaker, the strong quarterly increase was also on the back of growth in atrial fibrillation Solutions at CER, Infection Control and Mechanical Circulatory Support business.
Medtronic PLC Price
Medtronic PLC Price | Medtronic PLC Quote
Additionally, strong demand for the company's suite of quadripolar cardiac resynchronization therapy-pacemakers along with growth in Mechanical Circulatory Support drove Heart Failure division revenues.
The FDA approval for Deep Brain Stimulation therapy as an adjunctive treatment to reduce partial-onset seizures raises hope for the company in the target medical market. Medtronic is also focusing on the geographical diversification of its businesses. The company is highly positive about its foray into the $1-billion standalone CGM (continuous glucose monitoring) market with its Guardian Connect.
We are currently upbeat about the company’s recently-launched restructuring initiative called Enterprise Excellence plan, aimed at $3-billion annual growth run rate savings by the end of fiscal 2022. Per Medtronic, this new program has been designed to increase its effectiveness as well as heighten growth-related reinvestment ability alongside providing a consistent boost to its margin expansion and driving the EPS leverage.
On the flip side, the company has been grappling with steep costs and expenses, weighing heavily on its margins. Also, its 2019 guidance remains conservative on the apprehension of a significant currency headwind.
Key Picks
A few better-ranked stocks in the MedTech space are Inogen Inc (INGN - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) . While Inogen and Patterson Companies carry a Zacks Rank #2 (Buy), Integer sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has an expected long-term earnings growth rate of 22.5% while the same for Integer Holdings and Patterson Companies is pegged at 15% and 8.3%, respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>